The fifth case is a key milestone in the study because a data safety monitoring board will be able to review the SynerFuse concept, according to a July 26 news release.
“We’re one step closer to demonstrating the viability of our non-narcotic solution for spinal fusion patients with chronic lower back pain,” SynerFuse CEO Justin Zenanko said in the release.
The combination procedure adds a neurostimulator to stimulate the dorsal root ganglion to provide relief to patients with back pain. The study will enroll up to 20 patients, the release said.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
